Since joining Putnam in 2000, Remco has served clients in the pharmaceutical, biotech and medical device industries on projects focused in both domestic and international markets. His therapeutic area experience includes Vaccines, Oncology, CNS, Immunology, Infectious Disease, and Women’s Health. Remco’s most recent area of focus has been assisting organizations in defining the potential value of new compounds, making informed portfolio prioritization decisions, and formulating clinical development and commercialization plans that maximize return on investment.
Eric’s specialty is advising on competitive strategy, helping clients to evaluate and identify the critical path to winning in competitive markets and to drive growth in new or developing markets. Eric’s work cuts across internal functional areas, building strategic alignment within organizations around the business case for strategic recommendations, and developing the confidence for cross-functional
His practice is primarily focused in oncology, rare disease and other specialty disease markets. Over the past dozen+ years leading projects at Putnam, Matt has had the opportunity to partner with a host of amazing clients to bring truly incredible advances in medicine to clinicians and patients, translating breakthroughs in science into outstanding commercial successes.
John has counseled senior executives at numerous leading pharmaceutical and biotechnology companies, providing strategic support and recommendations on a wide array of issues, including pricing, contracting and reimbursement strategies, corporate strategy, new product commercialization, clinical trial development, and sales force optimization strategies. John has extensive experience in specialty pharmaceutical markets that comprise Oncology, Neurology, Immunology,
Shauna joined Putnam in 2019 as the firm’s Chief Financial Officer. She oversees the financial planning and reporting, accounting, tax, and treasury functions for the company and provides financial strategic oversight of the company’s long-term plans and goals. Prior to joining Putnam Shauna was the Chief Financial Officer at a high growth healthcare financial management
Prior to joining Putnam, Maeghan was the Chief of Staff for Deloitte LLP’s Chief Strategy Officer. Additionally she has held various roles as a healthcare life sciences consultant and talent strategist at Deloitte Consulting and Deloitte LLP. Maeghan helps organizations tackle their most complex talent and HR challenges and now applies her consulting and operations
Recent engagements have included pricing / managed markets strategy development, portfolio prioritization, medical adherence analysis, physician segmentation and opportunity analysis, and product forecasting. He has extensive expertise in advanced quantitative analyses (quantitative primary research, medical claims analysis, forecasting / scenario modeling) and has worked in a number of therapeutic areas including asthma, osteoporosis, cardiovascular, oncology
He has broad experience working across client functional groups including marketing, finance, and medical affairs, across geographies with his extensive work in the EU, US, and emerging markets, and across therapeutic areas, including vaccines, oncology, rheumatology, cardiology, and neurology. He has a sterling track record of helping clients achieve impactful results. Prior to joining Putnam,
Leveraging his experience with both pipeline and established products, prevalent and rare diseases, and US and global markets, Joseph draws upon a diverse problem-solving toolkit to add breadth and depth to his clients’ strategic analysis and planning. Prior to joining Putnam, Joseph founded and led a government-funded venture to develop next-generation alternative energy products. Joseph
He has a wealth of experience in specialty pharma and biotech markets including Oncology, Immunology, Endocrinology, Neuroscience, and Anti-infectives. Prior to joining Putnam, Sean was a research scientist in oncology and a consultant at L.E.K. Consulting. He recently re-joined Putnam to help start an office in San Francisco, after several years at Genentech in Market
My projects at Putnam dig deeply at the science of many of the biggest drugs, and then pivots into identifying or analyzing for business opportunities within the context of the science.
Alex has worked with a diverse global and start-up pharmaceutical, biotechnology, surgical device, and diagnostics clientele across product life cycle and functional areas including early-stage and in-line commercial, pricing and market access, and business analytics. Recent TA experience includes oncology (solid and hematological malignancies; targeted therapies, immuno-oncology, and CAR-T), benign hematology, allergy/immunology, respiratory medicine, autoimmune
I work with the partners, team, and clients to draw insights from primary and secondary data and provide strategies for supporting clinical and commercial development of pharmaceutical products.
My role is exciting because it allows me to take on a wide range of different responsibilities from performing in-depth data analysis, to helping develop hypotheses and storylines for the overall project, to manage the workstreams of newer members of the team.
As a former bench scientist, I find it exciting to work on projects that involve cutting-edge technologies and breakthrough therapies that have a direct clinical impact. I am able to leverage my research expertise by providing scientific and analytical insight into the development of business strategies that help our clients tackle challenging problems.
Tommy advises Putnam’s leading pharmaceutical and biotechnology clients on a broad array of commercial strategy topics. His project work focuses on new product opportunity assessments, launch planning, market access approaches, and contracting strategies. Since joining Putnam in 2014, he has supported the development and commercialization of over 25 biopharmaceutical products, combining his expertise in primary
I develop and promote best practices and standards for Putnam’s primary market research. I really enjoy working with our teams to find creative solutions to their research challenges.
Putnam is a fantastic place where everyone cares deeply about each other and the success of the team. As a Life Sciences Consultant, I’m often the scientific expert on my case team. I’ve leveraged my background experience and contributed from day one while learning new consulting and business skills.
Collectively, Putnam employees speak a total of 22 languages
I feel fortunate for the opportunity that Putnam has afforded me to help solve intellectually stimulating problems related to innovative pharma therapies across a wide range of therapeutic areas. The hard and soft skills that Putnam allows you to build and hone right from the beginning are indispensable.
At Putnam, I utilize my scientific background and critical thinking skills to help our teams provide meaningful solutions for our clients. It is extremely rewarding to team up with such high-caliber individuals to make an impact at the cutting-edge of the healthcare industry.
At Putnam, I’ve enjoyed working on a variety of global projects across multiple therapeutic areas within the life science industry. Small teams and mentors create a great culture with numerous opportunities to contribute, learn, and take on more responsibility.
Putnam was founded in 1988
91% of Putnam employees have worked on a case looking at global markets
Putnam has completed cases in over 35 therapeutic areas
77% of Putnam projects are serving clients who have trusted us with important projects 5 + years
Putnam focuses solely on the life science industries, allowing us to provide unparalleled depth, experience and insight into our client’s most complex challenges.
We do not define our client’s issue to fit our capabilities. Instead, we listen to their needs and tailor our comprehensive set of tools, techniques and expertise to quickly bring clarity to complex issues facing our clients.
Understanding the global challenges facing our clients enables us to provide customized, actionable and strategic recommendations that draw on deep therapeutic area and functional expertise.
